Omnicell Q2 adjusted EPS beats estimates, but tightens 2026 revenue guidance

Overview

• US healthcare technology firm's Q2 revenue rose 7% yr/yr to $312 mln

• Adjusted EPS for Q2 was $0.94, beating analyst expectations

• Q2 results benefited from $15 mln in tariff refunds, boosting profitability

Outlook

• Omnicell raises full-year 2026 non-GAAP EBITDA guidance to $175 mln-$185 mln

• Company tightens full-year 2026 revenue guidance to $1.225 bln-$1.245 bln

• Omnicell expects full-year 2026 non-GAAP EPS of $2.15-$2.30

Result Drivers

• CONNECTED DEVICE DEMAND - Co said revenue growth was driven by steady execution across its connected device portfolio in North America and international markets

• SERVICES GROWTH - Increases in SaaS, Expert Services, and technical services revenues contributed to higher total revenue

• TARIFF REFUND - $15 mln in refunds for previously paid tariffs reduced cost of revenues and boosted profitability in the quarter

Company press release: ID:nBw6H97KQa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment technology peer group is "buy"

• Wall Street's median 12-month price target for Omnicell Inc is $60.00, about 44.9% above its July 29 closing price of $41.40

• The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads

• July 27 - Netherlands' Philips lifts annual profit, cash flow outlook after US tariff refund

• July 29 - GE HealthCare tops quarterly estimates, weighs patient care unit sale

• July 29 - Waystar Q2 revenue beats analyst expectations

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)